Reneuron (RENE.L) is a stem cell research company whose focus is on therapies targeting areas of poorly met medical need, including peripheral arterial disease, stroke, and retinal diseases. RENE is currently testing the effects of neural stem cells on spines for neuroregeneration, and is testing the use of fetal stem cells on stroke patients.
A UK company, used as a scientific comparable due to status of trials and disease state.
February 24, 2022
RegMed Investors’ (RMi) pre-open: the invasion/attack has begun shaking global markets
February 23, 2022
RegMed Investors’ (RMi) closing bell: what happened, blood from the past and on-going sessions drowns sentiment
February 22, 2022
RegMed Investors’ (RMi) closing bell: stuck in the penalty box
February 18, 2022
RegMed Investors’ (RMi) closing bell: what has changed, an escalation of fears
February 18, 2022
RegMed Investors’ (RMi) pre-open: a dry-up in liquidity
February 17, 2022
RegMed Investors’ (RMi) closing bell: yet another cell and gene therapy sector sell-off
February 16, 2022
RegMed Investors’ (RMi) closing bell: the sectors back to its losing way
February 15, 2022
RegMed Investors’ (RMi) closing bell: a beautiful day in the sector’s neighborhood
February 15, 2022
RegMed Investors’ (RMi) pre-open: a tailwind of sharply higher futures due to past headlines
February 14, 2022
RegMed Investors’ (RMi) closing bell: interpreting the cell and gene therapy sector’s decline
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors